SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059084
Filing Date
2024-05-14
Accepted
2024-05-14 07:31:40
Documents
66
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20240331.htm   iXBRL 10-Q 1233754
2 EX-31.1 acrv-ex31_1.htm EX-31.1 15325
3 EX-31.2 acrv-ex31_2.htm EX-31.2 15303
4 EX-32.1 acrv-ex32_1.htm EX-32.1 9701
5 EX-32.2 acrv-ex32_2.htm EX-32.2 9684
  Complete submission text file 0000950170-24-059084.txt   6436748

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20240331.xsd EX-101.SCH 1219061
69 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20240331_htm.xml XML 984679
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 24941467
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)